<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04064463</url>
  </required_header>
  <id_info>
    <org_study_id>19-146-2</org_study_id>
    <nct_id>NCT04064463</nct_id>
  </id_info>
  <brief_title>Dual Reinforcement Contingency Management for Alcohol Use Disorders</brief_title>
  <acronym>Peth</acronym>
  <official_title>Dual Reinforcement Contingency Management for Alcohol Use Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phosphatidylethanol (PEth) is a direct biomarker of alcohol that can detect moderate to heavy
      drinking with high sensitivity and specificity over 3-week periods. Reinforcing negative PEth
      results alongside attendance may increase the proportion of participants who respond to CM
      during and post treatment. In the proposed study, the investigators will collect PEth samples
      every 3 weeks for 12 weeks in 150 participants initiating outpatient treatment for alcohol
      use disorders. Using a two-group randomized design, participants will be assigned to standard
      care with PEth monitoring alone or with CM for attending treatment and submitting PEth
      negative samples. Compared to standard care and monitoring, the investigators expect that the
      CM intervention will result in greater attendance, more PEth negative samples, and higher
      proportions of self-reported non-drinking days, along with lower proportions of heavy
      drinking days, over the short term and the long term, measured throughout a 12-month
      follow-up. The investigators anticipate that the reinforcement intervention may decrease
      other drug use and sexual risk behaviors that spread HIV, reduce psychiatric symptoms, and
      improve quality of life as well.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    due to COVID-19
  </why_stopped>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Group attendance</measure>
    <time_frame>12 weeks</time_frame>
    <description>longest consecutive days attended groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alcohol abstinence</measure>
    <time_frame>12 weeks</time_frame>
    <description>number of negative PEth samples</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <condition>Contingency Management</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard care plus contingency management</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>standard treatment for substance use disorders, along with sample monitoring</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Contingency management</intervention_name>
    <description>Participants can earn reinforcement for attending group and abstinence from alcohol</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  in intensive outpatient treatment

          -  DSM-5 diagnosis of an alcohol use disorder

        Exclusion Criteria:

          -  have a condition that may hinder study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheila Alessi, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Village</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UConn Health</investigator_affiliation>
    <investigator_full_name>Sheila Alessi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

